Articles by Stephanie Sutton - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Stephanie Sutton

Lycera and MSD Collaborate on Autoimmune Therapies

Feb 12, 2013

The biopharmaceutical company lycera has announced a collaboration agreement with Merck, Sharpe & Dohme (MSD) that will focus on developing and commercializing small-molecule therapies for treating a range of autoimmune diseases.

Drug Discovery Initiative Launched in Europe

Feb 11, 2013

An international consortium of pharmaceutical companies, academia, research organisations and other related entities have launched a new platform to help enhance drug discovery in Europe.

European Commission Investigates J&J and Novartis

Feb 1, 2013

The European Commission claims that Johnson & Johnson and Novartis may have breached European antitrust rules.

GSK Announces Joint Venture for Pediatric Vaccine

Jan 28, 2013

GlaxoSmithKline has formed a joint venture with Indian vaccines company Biological E to research and develop a six-in-one combination pediatric vaccine to help protect children in India and other developing countries from certain infectious diseases.

EMA Updates Guideline for Anticancer Medicines

Jan 14, 2013

The European Medicines Agency has revised its guideline for the evaluation of anticancer medicinal products.

Partnership Aims to Advance Malaria Vaccine R&D

Jan 7, 2013

The PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals have announced a follow-on collaboration to advance the development of malaria vaccines and new vaccine delivery technologies.

EMA Reveals Work Program for 2013

Dec 31, 2012

The management board of the European Medicines Agency (EMA) has endorsed the agency?s work programme and budget for 2013, which includes a budget of EUR231.6 million, a slight increase over 2012.

GSK Partners with Vodafone for Vaccinations

Dec 24, 2012

GlaxoSmithKline has formed a partnership with Vodafone to use mobile technology to help vaccinate more children against common infectious diseases in Africa.

Vivalis and Intercell to Create New Biotech Company

Dec 18, 2012

Vivalis and Intercell have agreed to the terms of a merger to create a new European biotechnology company called Valneva that will specialise in vaccines and antibodies.

ADVERTISEMENT

ADVERTISEMENT

Click here